Mainz Biomed has entered a partnership with Dante Labs to commercialise its flagship product, ColoAlert, in Italy and the United Arab Emirates (UAE).
ColoAlert is a non-invasive at-home detection test for colorectal cancer (CRC). The test is designed to detect tumour DNA and CRC cases in their earliest stages by analysing stool samples.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The test kit includes a stool collector, instructions for use and shipping instructions. After use, the kit can be sent through regular mail to a local laboratory for analysis and results.
The product is CE-IVD marked and currently available in several countries in the Europe Union (EU).
Under the new collaboration, Mainz will leverage Dante’s various established commercial channels to introduce ColoAlert in Italy and the UAE.
Initially, the test samples will be processed at Mainz’s in-house facility.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDante will later procure Mainz’s CE-IVD polymerase chain reaction (PCR) assay kits and transfer test processing capabilities to its automated genomic sequencing laboratories located in the two countries.
Mainz Biomed CEO Guido Baechler said: “As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it’s an absolute pleasure to partner with an industry leader such as Dante Labs.
“Our differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like-minded companies, such as Dante Labs, who share our passion for forward-thinking diagnostic test development and marketing strategies.”
CRC is the second leading cause of cancer death in the US and Europe. However, early detection increases survival rates to higher than 90%.
In February, Mainz launched a clinical study to assess the integration of a new mRNA biomarkers portfolio into the ColoAlert test.
